Chimeric Therapeutics Limited

ASX (AUD): Chimeric Therapeutics Limited (CHM)

Last Price

0.01

Today's Change

-0.004 (28.57%)

Day's Change

0.009 - 0.012

Trading Volume

15,777,723

Overview

Market Cap

14 Million

Shares Outstanding

1 Billion

Avg Volume

953,053

Avg Price (50 Days)

0.02

Avg Price (200 Days)

0.02

PE Ratio

-0.50

EPS

-0.02

Earnings Announcement

19-Feb-2025

Previous Close

0.01

Open

0.01

Day's Range

0.009 - 0.012

Year Range

0.009 - 0.047

Trading Volume

15,777,723

Price Change Highlight

1 Day Change

-28.57%

5 Day Change

-28.57%

1 Month Change

-28.57%

3 Month Change

-47.37%

6 Month Change

-67.74%

Ytd Change

-72.22%

1 Year Change

-72.97%

3 Year Change

-96.77%

5 Year Change

-96.61%

10 Year Change

-96.61%

Max Change

-96.61%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment